{"schema":"hottub-news/story/v1","story":"st_eu4nntpuwrkm5tuo47aa","title":"Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/innovent-announces-expansion-of-global-phase-3-marslight-11-study-of-eu4nntpuwr","count":1,"items":[{"id":"n_eu4nntpuwrkm5tuo47aa","seq":502059,"kind":"article","title":"Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC","url":"https://www.rdrnews.com/online_features/press_releases/innovent-announces-expansion-of-global-phase-3-marslight-11-study-of-ibi363-tak-928-alpha/article_c4caf8c3-39c5-567d-b0c9-9621f98696ee.html","summary":"SAN FRANCISCO and SUZHOU, China, Sept. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic…","published":"2026-09-28T00:00:00Z","seen":"2026-09-28T19:01:26Z","lang":"en","country":"US","source":{"id":"kite-rdrnews-com-059ec0","name":"rdrnews.com","domain":"rdrnews.com","outlet":{"wikidata":"Q7370099","name":"Roswell Daily Record","type":"newspaper","country":"US","designations":["newspaper"]}},"via":"kite-rdrnews-com-059ec0","topics":["new-mexico"],"authors":["By Innovent Biologics"],"entities":[{"id":"Q30296199","name":"Innovent","type":"org"},{"id":"Q3658562","name":"non-small-cell lung carcinoma","type":"other"}],"story":"st_eu4nntpuwrkm5tuo47aa","category":"science-technology","category_p":0.6899999976158142,"category2":"health","sentiment":"neutral","tone":0.17000000178813934,"political":0.03999999910593033}]}